Solid phase sandwich ELISA for the determination of Human VEGFR-3/Flt-4 in human serum, EDTA-plasma and cell culture supernatant. For research use only, not for use in diagnostic procedures.<br><br>
All members of the VEGF family (VEGF-A, -B, -C, -D, -E) stimulate cellular responses by binding to tyrosine kinase receptors (the VEGFRs) on the cell surface, causing them to dimerize and become activated through transphosphorylation. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. The VEGFR-3, which is also known as Flt-4 (Fms-like tyrosine kinase 4), has been discovered as a third receptor. It is known that VEGFR-3/Flt-4 mediates lymphangiogenesis in response to VEGF-C and VEGF-D. This product is capable of the determination of human VEGFR-3/Flt-4 in human serum, EDTA-plasma or cell culture supernatant.
- Assay Description:
- 1 hour incubation (37°C) + 30 min. (4°C) + 30 min. (RT) = 2 hours total incubation time
- Catalog number:
- 27779
- configuration:
- 96 Determinations, 12x8 removable strips
- controls:
- None provided
- design:
- Solid phase sandwich ELISA using 2 kinds of high specific antibodies
- FDA Status:
- For research use only, not for use in diagnostic procedures
- MSDS:
- notes:
- The protocol for this product (see above) is intended to serve as an example only. Please refer to the Instructions For Use provided with the assay kit for precise details.
- Protocol:
- Sample types:
- Human serum, EDTA-plasma and cell culture supernatant
- Sample volume:
- 100 μL of properly diluted unknown / determination
- standards:
- 8 standards, serially diluted from 1 prepared lyophilized standard
- Standard range:
- 0 / 0.03 - 2.00 ng/mL
- storage:
- 2 - 8 °C
- sensitivity:
- 0.004 ng/mL
- Species:
- Human
- Additional info:
